Pharmaceuticals in the Trade Related Aspects of the Intellectual Property Rights (TRIPS) Agreement of the World Trade Organization - A Briefing on Trips
(2000; 20 pages)
Table des matières
Afficher le documentPreface
Afficher le documentIntroduction
Afficher le document1. What is WTO and what is the TRIPS Agreement?
Afficher le document2. What are the implications of the TRIPS Agreement on patents for pharmaceutical products?
Afficher le document3. How long are patented drugs protected by the TRIPS Agreement?
Afficher le document4. Does the TRIPS Agreement strengthen the monopoly patenting of processes?
Afficher le document5. What are the impacts of the TRIPS Agreement on prices and availability of pharmaceutical products?
Afficher le document6. What can Member States do to counteract the impact of TRIPS on drug prices?
Afficher le document7. The balance between the protection of intellectual property rights and public policy objectives
Afficher le document8. When will the TRIPS Agreement be applied?
Afficher le document9. What is WHO’s view and position on WTO/TRIPS Agreement?
Afficher le document10. What are the recommendations for Member States?
 

10. What are the recommendations for Member States?

• Public health concerns should be considered when implementing the TRIPS Agreement. Member States should provide limited exceptions to the patent holder’s exclusive rights in their domestic laws. The issue of compulsory licenses and parallel imports should be allowed.

• Member countries should make the fullest use of the periods of transition for incorporating the necessary provisions into their domestic laws.

• Member countries should undertake necessary measures to monitor the impact of the Agreement on access to essential drugs.

BS/lvvg/TE/17/04/2000/WTO-TRIPS
Agreement Rev. 25 July 2000

vers la section précédente
 

Dernière mise à jour: le 3 mai 2013